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Abstract 
Purpose of Review: Small intestinal bacterial overgrowth (SIBO) has been proposed as a cause of 
irritable bowel syndrome (IBS). However, this relationship has been subject to controversy. This 
review aims to provide a current perspective on the SIBO-IBS hypothesis.  
Recent Findings: Case-control studies evaluating the prevalence of SIBO in IBS and healthy subjects 
have shown conflicting results. Moreover, the tests available in routine clinical practice to diagnose 
SIBO are not valid and lack both sensitivity and specificity. Hence, interpreting the effect of 
interventions based on these tests is fraught with uncertainty. Furthermore, the SIBO-IBS hypothesis 
has paved the way to assess antibiotic therapy in non-constipated IBS, with rifaximin, a non-
absorbable antibiotic, showing modest but significant clinical benefit. However, subjects were not 
tested for SIBO and the mechanism of action of rifaximin in IBS remains to be elucidated. Preliminary 
data suggests rifaximin decreases microbial richness and previous studies have noted antibacterial 
interventions in IBS to reduce colonic fermentation and improve symptoms. The advent of rapid 
culture-independent molecular techniques is a promising tool that will seek to clarify and advance 
our understanding of the gut microbial function. 
Summary: The SIBO-IBS hypothesis lacks convincing evidence but remains under scrutiny. The 
mechanism resulting in symptom improvement after rifaximin treatment in some IBS subjects 
requires exploration. Novel molecular techniques provide an exciting and challenging opportunity to 
explore the host-gut microbiota interaction. 
Keywords: Small intestinal bacterial overgrowth, irritable bowel syndrome, hydrogen breath tests, 
rifaximin 
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Introduction 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that manifests with symptoms 
of abdominal pain and altered bowel habit in the absence of abnormal findings on routine clinical 
tests explaining the symptoms. IBS has a prevalence of approximately 10% in adults, shows a female 
preponderance, and is more common in younger individuals. The burden of illness is significant with 
IBS having a chronic remitting-relapsing nature and is often associated with extra-intestinal somatic 
symptoms as well as fatigue, depression, anxiety, and diminished quality of life.1 
The exact cause of IBS is unknown although the prevailing hypothesis is a disorder of the brain-gut 
axis as demonstrated by alterations in gut immunity, visceral hypersensitivity, enteric motor function 
disturbances and central pain processing.1 The intestinal microbiota has also been shown to be 
perturbed in a subset of IBS subjects compared to healthy controls,2 with its interactive crosstalk at 
the intestinal mucosal border possibly contributing towards the pathophysiology of IBS.3 With this in 
regard, it has been suggested that small intestinal bacterial overgrowth (SIBO) may play a pivotal 
role in the aetiology of IBS, although this has been debated.4-6 Herein, we discuss the constituents of 
the normal small intestinal flora, its disturbances leading to SIBO, and the methods used in clinical 
practise to diagnose SIBO along with their shortcomings. Finally, we discuss whether there is 
sufficient evidence to currently support the SIBO-IBS hypothesis and how novel technical advances 
in microbial analysis may help further our understanding. 
The intestinal flora  
The influx of gastric acid into the proximal small intestine and the propagating activity of the 
migrating motor complex lead to low bacterial counts ranging from 100-103 colony forming units per 
ml (CFU/ml) in the duodenum and jejunum, consisting predominantly of gram-positive aerobes. 
Distally, there is an increase in bacterial counts with the ileum having between 105-108 CFU/ml of 
colonic-type bacteria which comprise gram negative aerobes, obligate anaerobes, and enterococci. 
In contrast to the relatively sparse bacterial counts in the small intestine, the colon has between 
1010-1012 CFU/ml.2  
Various conditions can lead to bacterial proliferation within the small intestine, thereby giving rise to 
SIBO.7 These include gastric achlorhydria secondary to proton-pump inhibitor usage or atrophic 
gastritis, small bowel stagnation secondary to alterations in upper gastrointestinal anatomy, and 
disorders affecting enteric motility such as diabetes mellitus and scleroderma. The development of 
SIBO under such circumstances correlates with clinical symptoms of diarrhoea, bloating, abdominal 
pain, weight loss, anaemia and malabsorption, which improve following treatment.7 
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Tests used to diagnose SIBO and their pitfalls 
The three tests currently available in routine clinical practise to make a diagnosis of SIBO are culture 
of small bowel aspirates, the glucose-hydrogen breath test (GHBT), and the lactulose-hydrogen 
breath test (LHBT). However, they all have inherent problems with regards to accuracy and 
interpretation, which renders their use in clinical practise questionable.8-11 
Small bowel aspirate and culture are considered the gold standard test, with a diagnosis of SIBO 
made on the basis of demonstrating >105 CFU/ml of colonic-type bacteria. However, this cut-off has 
been challenged as being too high given that it was determined from samples following surgical 
diversion and not healthy controls.12 Instead, some have proposed a level of >103 CFU/ml to denote 
SIBO.12 Furthermore, the technique to obtain small bowel aspirate is cumbersome, invasive, and 
runs the risk of contamination from oral flora. In addition, obligate anaerobes may not be detected 
and aspiration of proximal small bowel contents will not necessarily address cases of SIBO affecting 
the distal small bowel. Hence, the sensitivity and specificity of small bowel aspirate to detect SIBO 
may be limited.9-11 
In contrast, the hydrogen breath tests are simple, non-invasive, and cheaper alternatives which are 
widely adopted in clinical practise. They work on the premise that hydrogen production in humans 
occurs only as a consequence of bacterial fermentation of carbohydrates. The hydrogen diffuses into 
the systemic circulation and is expired by the lungs where it can be detected using gas 
chromatography. As glucose is a monosaccharide which undergoes rapid absorption within the 
proximal small intestine, thereby theoretically avoiding exposure to distal colonic-type bacteria, a 
hydrogen rise is not expected in subjects without SIBO. In contrast, lactulose is a non-digestible 
disaccharide which passes through the small bowel followed by fermentation by colonic-type 
bacteria, so a hydrogen-rise is expected albeit not immediately after ingestion. Hence, through 
biological plausibility, an early detectable rise in hydrogen following a GHBT or LHBT has been used 
in clinical practise to imply premature fermentation due to SIBO.9-11 
However, the GHBT and LHBT have several shortcomings. High basal hydrogen-levels may be 
detected, which can be avoided by following a low-fibre diet a day before the procedure. Hydrogen-
levels can increase with smoking and decrease with exercise so both events are prohibited around 
the time of the test. False positives can also occur through immediate fermentation by oral bacteria, 
although aseptic mouthwash pre-procedure aims to counteract this.9-11 With regards to the 
individual tests, concerns pertaining to the GHBT are that it lacks sensitivity given that proximal 
absorption of glucose will miss distal cases of SIBO. In contrast, lactulose transits the whole small 
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bowel and would pick up all SIBO cases; consequently the LHBT has been the most widely adopted 
test in clinical studies. 
Additional uncertainties relate to the optimal dosage of substrate for breath tests and what 
constitutes an abnormal and premature hydrogen-rise. The dosage of glucose and lactulose 
substrate has varied in studies from 50-100g and 10-25g, respectively, with a hydrogen-rise of 10 to 
20 parts per million (ppm) being used to diagnose SIBO. Historically, a double-peak sign was used to 
identify SIBO with LHBT, with the first peak denoting small bowel fermentation (i.e. SIBO) and the 
second peak normal colonic fermentation. However, this lacks validity as commonly there is just one 
peak seen or in the case of two-peaks the first may occur when the substrate has already reached 
the caecum.8-11 Subsequently, a single hydrogen-rise of 12-20ppm within 90 minutes, or in some 
cases 180 minutes, has been proposed to diagnose SIBO instead. However, concerns remained that 
this may still not be detecting SIBO as both IBS and healthy subjects have variable oro-caecal 
times;9,13 in healthy subjects this is on average 90 minutes, and therefore in around 50% of cases an 
early hydrogen-rise will be indicative of rapid intestinal transit with ensuing colonic fermentation.9 
Finally, lactulose accelerates intestinal transit and further complicates interptretation.14 
Indeed, a well-designed study has confirmed these suspicions.15 Forty subjects with IBS ingested 10g 
of lactulose along with a radio-labelled test meal containing 99mTc. Subsequent serial LHBT and 
nuclear scintigraphic scanning were performed. The investigators noted that 63% had abnormal 
LHBT at 180 minutes and 35% at 90 minutes. The oro-caecal time based on scintigraphic scanning 
ranged from 10 to 220 minutes and correlated with IBS-subtype. Importantly, at the time of 
hydrogen-rise the accumulation of 99mTc in the caecum was >5% in 88% of cases. In summary, this 
study suggests that an abnormal hydrogen-rise with the LHBT in IBS patients can be explained by 
variations in the oro-caecal transit times and therefore does not support a diagnosis of SIBO.15 
The specificity of the GHBT has also come under similar scrutiny.16,17 A historical study, utilising GHBT 
with concurrent scintigraphy, noted 8 of 25 subjects with chronic diarrhoea (and intact 
gastrointestinal anatomy) to have rapid intestinal transit leading to colonic hydrogen production.16 
More recently, a retrospective study of 139 patients undergoing GHBT and concurrent scintigraphy 
has demonstrated high rates of false-positive results for SIBO.17 Of the 33% (n=46) of subjects with 
abnormal GHBT at 90 minutes, 48% (n=22) had a hydrogen-rise after the glucose substrate had 
reached the caecum. Subgroup analysis demonstrated that i) for the 45 patients with a history of 
upper gastrointestinal surgery, 69% (n=31) had abnormal GHBT of which 65% (n=20) were false 
positives and ii) for the 94 patients without gastrointestinal surgery, 16% (n=15) had abnormal GHBT 
of which 13% (n=2) were false positives. Subjects with false-positive results had shorter mean oro-
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caecal time (18 minutes) compared with true-positive (79 minutes) or negative results (86 minutes). 
The investigators conclude that almost half of positive GHBT results are false positives and that 
concurrent use of scintigraphy will be a valuable tool in discriminating between true and false-
positives.17,18 
In summary, the tests used to diagnose SIBO lack sensitivity and specificity.9-11 An expert consensus 
working group initially concluded that the diagnostic accuracy of GHBT was 71.7% whereas that of 
LHBT was 55.1%.19 However, in light of recent studies further emphasising the limitations of 
hydrogen breath tests,15,17 these values could potentially be challenged. Future studies should aim to 
utilise the rapid molecular approaches that have largely replaced cultural approaches for 
enumeration of the dominant GI microbiota.2 These include 16S RNA-based microbiota profiling 
which allows quantitative and qualitative analysis of gastrointestinal mucosal and luminal content 
ŵŝĐƌŽďŝŽƚĂ ?DŽƌĞŽǀĞƌ ? ?-ŽŵŝĐ ?ďĂƐĞĚĂŶĂůǇƐŝƐĂůůŽǁƐŝŶĚĞƉƚŚƐƚƵĚǇŽĨŵŝĐƌŽďŝĂůĨƵŶĐƚŝŽŶ ?2 This will 
provide important insights into the interactions between the host and gut microbiota, and the 
relative importance of small bowel bacteria in the pathophysiology of IBS. 
The relationship between SIBO and IBS 
The controversy surrounding SIBO as a cause for IBS has spanned over a decade. The main 
proponents for the SIBO-IBS hypothesis initially showed that a positive LHBT was seen in 78% of IBS 
cases and that in a subset open-label antibiotic treatment led to a negative LHBT and clinical 
improvement.20 Following on, a case-control study by the same group noted a positive LHBT in 84% 
of IBS cases compared with 20% of healthy controls. Double-blind placebo-controlled treatment with 
neomycin in the LHBT-positive IBS group led to normalisation of LHBT and symptom improvement.21 
Given that neomycin can lead to bacterial resistance the investigators turned their attention to the 
safety and efficacy of rifaximin, a non-absorbable antibiotic, in IBS.  
The TARGET 1 and 2 trials were two identical multi-centre, double-blind, placebo-controlled studies 
together randomising 1258 IBS subjects without constipation to either placebo or rifaximin 550mg 
TDS for 14 days.22 Unfortunately, the subjects were not tested for SIBO. By week 4 there was a 
significant, albeit modest, improvement in global IBS symptoms in the rifaximin group compared to 
the placebo group (40.7% vs. 31.7%, ѐс9%, p<0.001), translating to a number needed to treat (NNT) 
of 11. Adverse events were similar between the groups and there were no cases of Clostridium 
difficile infection. In addition, a greater percentage of rifaximin- than placebo-treated subjects 
reported durable improvement in IBS symptoms during the 10-week follow-up period. However, the 
study was not designed to determine the persistence of this treatment effect beyond this time point.  
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This recently published TARGET 3 was a key study designed to assess the safety and efficacy of 
repeated courses of rifaximin in subjects with diarrhoea-predominant IBS.23 Of 2579 IBS patients 
receiving rifaximin, 1074 (41.6%) showed clinical improvement within 4 weeks and were followed up 
for 18 weeks. Of the initial responders, 636 (59.2%) relapsed and were randomised in a double-blind 
manner to receive either a 2-week course of rifaximin 550mg or placebo TDS. A recapture response 
rate within 4 weeks was significantly greater with rifaximin than placebo (38.1% vs. 31.5%, ѐс7%, 
p=0.03). Adverse events were low and similar between the groups. These findings suggest that 
rifaximin is efficacious and safe to use in diarrhoea-predominant IBS. Since May 2015 rifaximin has 
been approved by the US Food and Drug Administration for the treatment of adult patients with 
diarrhoea-predominant IBS. However, rifaximin is an expensive drug (~$50 per day), and the modest 
efficacy, as well as the potential need for repeated antibiotic prescriptions in a relatively young 
patient group does raise apprehension. 
The accumulating evidence suggests a relationship between the gut microbiota and IBS,2 and that 
this interplay can be modulated via antibiotics.24 However, in some instances, the data has been 
interpreted to promulgate the SIBO-IBS hypothesis although this assumption cannot be made for 
various reasons, which include: 
1. Other groups evaluating the yield of a positive small bowel aspirate or hydrogen breath tests 
in subjects with IBS and healthy controls have shown conflicting results (Table 1).21,25-38 A 
systematic review and meta-analysis in 2009 found the pooled odds ratio for any positive 
test was 3-5 fold times greater in IBS than controls.39 However, this was not significant when 
the criteria that gave the lowest prevalence was used, but was significant when the criteria 
that gave the highest prevalence was used. Importantly, there was marked statistical 
heterogeneity between the studies and funnel plot asymmetry to suggest publication bias or 
other small study effects.39 Finally, most studies did not take into consideration confounding 
factors such as proton pump inhibitor usage, which are commonly consumed by IBS subjects 
and independently associated with SIBO.40 As a result the association between SIBO and IBS 
was deemed uncertain.39 
A few studies have now used culture-independent molecular techniques to analyse small 
bowel microbiota in IBS and healthy controls, with conflicting results.41-44 In general, these 
studies have been of relatively small sample-size and used different techniques to obtain 
small bowel microbial content (aspirate/mucosal brushing/biopsies).41-44 Large-scale uniform 
studies using modern culture-independent techniques are needed. 
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2. A fundamental issue is that the currently available tests are poor methods to diagnose and 
monitor SIBO.9-11 The LHBT, which has been the most frequently used for this purpose in 
clinical studies, commonly measures oral-caecal time and colonic fermentation and 
therefore does not reliably diagnose SIBO.15 The GHBT has also faced similar criticisms. 
Hence, it can be argued that studies using breath tests to diagnose SIBO and subsequently 
interpret the effect of antibiotics as altering the small intestinal microbiota may be 
misconstrued. Rather, the evidence suggests modulation of colonic microbiota. This would 
be supported by a recent case-control study using wireless motility capsule to show that 
intestinal intraluminal pH (a surrogate marker for fermentation) remains similar in the small 
bowel of IBS and healthy controls, but significantly drops in the colon for those with IBS 
compared with healthy controls.45 Furthermore, previous studies have demonstrated dietary 
or antibacterial interventions to reduce colonic fermentation and improve IBS symptoms.46,47 
With regards to the pathophysiological mechanism of rifaximin in IBS, preliminary data has 
shown a decrease in gut microbial richness although large-scale studies are needed.48  
3. Whereas the biopsychosocial model for IBS is accepted, the SIBO-IBS hypothesis has been 
questioned from an epidemiological and evolutionary perspective.6 For example, the SIBO-
IBS hypothesis suggests that infection causes IBS and that alternate competing hypothesis 
are a secondary epiphenomenon. However, antibiotics have a NNT of 11 which is less 
favourable compared to some of the treatment modalities used to address the brain-gut axis 
and not SIBO. For example, the NNT with antidepressants, antispasmodics, peppermint oil 
and placebo without deception has been shown to range from 2.5 to 5.6 However, no head-
to-head trials exist. 
Furthermore, whereas a dose-symptom correlation relationship has been established for 
psychosocial trauma and IBS, this has not been shown for SIBO and IBS.6 A prospective dual-
centre US study evaluating subjects with unexplained gastrointestinal symptoms (seemingly 
characteristic of IBS) found there to be no difference in overall symptom scores between 
those testing positive against those testing negative for SIBO, when using either small bowel 
aspirate or GHBT. Moreover, there was no difference in any symptom scores between 
subjects with small bowel aspirate of >103 CFU/ml vs. >105 CFU/ml.49 Hence, even if SIBO is 
present in IBS, its relevance for symptoms is unclear.  
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Conclusion 
There is undoubtedly great interest in underpinning the role of intestinal microbiota in IBS. The 
evidence suggests that this interaction appears to be with regards to the colonic microbiota and its 
crosstalk with the host. In contrast, the evidence for SIBO and IBS is shrouded with controversy, 
predominantly due to the fact that the tests used in clinical practise to diagnose SIBO are not valid. 
With this is mind, SIBO cannot be currently found guilty for causing IBS. Nevertheless, it remains a 
suspect under surveillance and with the advent of culture-independent molecular techniques future 
studies should aim to advance our understanding of the gut microbiome for symptom generation in 
patients with IBS. 
 
Key points 
- Small intestinal bacterial overgrowth (SIBO) has been proposed as a cause of IBS. 
- However, the tests used in routine clinical practise to diagnose SIBO lack standardisation and 
validity, which leaves the SIBO-IBS hypothesis open to debate when evaluating the effects of 
interventions.  
- Rifaximin has recently been shown to be of benefit in non-constipated IBS subjects but with 
no information about the presence of SIBO. 
- Preliminary data suggests rifaximin to reduce microbial richness, although large-scale studies 
are needed to see how this relates to symptomatology. 
- Future large-scale studies should utilise novel culture-independent molecular approaches to 
investigate the host-gut microbial interactions to determine the role of small bowel bacteria 
in IBS pathophysiology.  
 
 
 
 
 
10 
 
Table 1: Case-control studies using small bowel aspirate or glucose/lactulose-hydrogen breath (GHBT, LHBT respectively) 
tests to investigate the association between SIBO and IBS in adults 
First 
author 
Year Country Number of IBS 
cases vs. healthy 
controls  
Test used to diagnose 
SIBO 
SIBO prevalence: 
IBS vs. healthy controls 
Pimentel21 2003 US 111 vs. 15 LHBT 84% vs. 20%,* 
Walters25 2005 Canada 39 vs. 20 LHBT: double peak 
 
LHBT: >20 ppm H2-rise 
within 90mins 
 
LHBT: >20 ppm H2-rise 
within 180 mins 
10% vs. 10% 
 
28% vs. 30% 
 
 
69% vs. 75% 
Lupascu26 2005 Italy 65 vs. 102 GHBT 31% vs. 4%,* 
Posserud27 2006 Sweden 162 vs. 26 
 
 
 
 
 
 
 
 
 
 
54 vs. 20 
 
46 vs. 21 
Jejunal aspirate >105 
CFU/ml (colonic 
bacteria) 
 
Jejunal aspirate ш5 x 103 
CFU/ml (any bacteria) 
 
Jejunal aspirate ш5 x 103 
CFU/ml (colonic 
bacteria)  
 
GHBT 
 
LHBT: double peak 
 
LHBT: >20 ppm H2-rise 
within 90mins 
 
LHBT: >20 ppm H2-rise 
within 180 mins 
4% vs. 4%  
 
 
 
43% vs. 12%,* 
 
 
11% vs. 4% 
 
 
 
2% vs. 0%  
 
15% vs.20%  
 
35% vs.45%  
 
 
78% vs. 70%  
Bratten28 2008 US 180 vs. 34 LHBT 74% vs. 85% 
Rana29 2008 India 225 vs. 100 GHBT 11% vs. 1%,* 
Parodi30 2009 Italy 130 vs. 70 GHBT 16% vs. 4.3%,* 
Ghoshal31 2010 India 192 vs. 51 GHBT 8.5% vs. 2% 
Lombardo32 2010 Italy 200 vs. 50 GHBT 24.5% vs. 6% 
Rana33 2012 India 175 vs. 150 LHBT 
GHBT 
34% vs. 30% 
6.2% vs. 0.7%,* 
Park34 2010 Korea 76 vs. 40 LHBT 44.7% vs.40% 
Sachdeva35 2011 India 59 vs. 37 GHBT 23.7% vs. 2.7%,* 
Moraru36 2014 Romania 331 vs. 105 GHBT 31.6% vs. 6.6%,* 
Abbasi37 2015 Iran 107 vs. 107 GHBT 37.4% vs. 12.1%,* 
Chu38 2016 China 89 vs. 13 LHBT: double peak 
 
LHBT: >20 ppm H2-rise 
within 90mins 
 
LHBT: >20 ppm H2-rise 
within 180 mins 
44% vs. 38% 
 
31% vs. 30% 
 
 
75% vs. 70% 
The * denotes significant results p<0.05 
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